Halia Therapeutics is a clinical-stage biopharmaceutical company with a ground-breaking and transformative approach to targeting chronic inflammation. Their pipeline of products allows for treating chronic disease in new ways by turning off the inflammatory signaling at the source. The team has developed a proprietary approach to inhibit inflammation, which has led to the design of potent and selective, small-molecule allosteric modulators that have shown activity against a broad range of disease models. Halia is led by an expert team of experienced and passionate scientists with decades of experience in drug discovery and development.